🔗 Share this article

Treasury head Reeves has revealed she is preparing "targeted measures to tackle household expense challenges" in the upcoming financial statement.

During an interview with the BBC, she emphasized that lowering price rises is a shared duty of both the administration and the central bank.

The UK's inflation rate is forecast to be the highest among the Group of Seven advanced economies this calendar year and next.

Potential Energy Cost Measures

Reports indicate the administration could intervene to bring down utility costs, for instance by cutting the current 5% level of VAT charged on energy supplies.

A further option is to reduce some of the regulatory levies currently included in household expenses.

Budgetary Constraints and Analyst Expectations

The administration will obtain the next assessment from the independent fiscal watchdog, the OBR, on the start of the week, which will reveal how much scope there is for these actions.

The expectation from most economists is that Reeves will have to declare higher taxes or expenditure reductions in order to adhere to her voluntary borrowing rules.

Earlier on Thursday, estimates showed there was a £22bn shortfall for the chancellor to address, which is at the more modest range of forecasts.

"It is a shared task between the Bank of England and the administration to further reduce some of the sources of price increases," Reeves informed the BBC in Washington, at the annual meetings of the International Monetary Fund and global financial institution.

Tax Pledges and Global Concerns

While much of the attention has been on likely tax rises, the Treasury chief said the latest data from the fiscal watchdog had not changed her pledge to manifesto promises not to increase tax levels on earnings tax, sales tax or social security contributions.

She attributed an "unpredictable world" with growing geopolitical and commercial concerns for the fiscal revenue measures, likely to be directed on those "most able to pay."

International Economic Tensions

Referring to apprehensions about the United Kingdom's economic relations with China she said: "Our security interests always come first."

Last week's statement by Chinese authorities to strengthen export controls on rare earths and other resources that are key for high-technology manufacturing led American leader Donald Trump to propose an additional 100% import tax on goods from the Asian country, raising the risk of an full-scale commercial conflict between the two global powers.

The American finance chief called China's action "economic coercion" and "a international production power grab."

Inquired about accepting the US offer to participate in its dispute with China, Reeves said she was "extremely troubled" by Chinese actions and encouraged the Beijing authorities "not to put up barriers and restrict access."

She said the move was "bad for the world economy and generates further headwinds."

"It is my opinion there are fields where we must confront Chinese policies, but there are also significant opportunities to trade with China's economy, including financial services and other areas of the economic system. We've got to get that equilibrium appropriate."

The chancellor also affirmed she was collaborating with international partners "on our own critical minerals strategy, so that we are reduced dependence."

NHS Medicine Costs and Investment

The Chancellor also admitted that the cost the NHS pays for medicines could increase as a result of current negotiations with the US government and its pharmaceutical firms, in exchange for reduced taxes and funding.

Some of the world's largest pharmaceutical manufacturers have said lately that they are either halting or scrapping projects in the United Kingdom, with several blaming the modest returns they are getting.

Last month, the Science Minister said the cost the health service pays for medicines would must rise to halt businesses and pharmaceutical investment departing from the United Kingdom.

Reeves informed media: "We have seen as a result of the pricing regime, that clinical trials, recent pharmaceuticals have not been available in the UK in the manner that they are in other European countries."

"We want to guarantee that patients receiving treatment from the National Health Service are can receive the best life-saving treatments in the globe. And so we are reviewing these issues, and... seeking to obtain additional investment into the UK."